Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSRCIS)

Drug Name
AMG 133 Drug Info
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMSRCIS

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric inhibitory polypeptide receptor (GIPR) TTYMKBE GIPR_HUMAN Antagonist/GLP1 agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Gastric inhibitory polypeptide receptor (GIPR) DTT GIPR 3.511 2.907 1.585 1
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Obesity
ICD Disease Classification 5B81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Gastric inhibitory polypeptide receptor (GIPR) DTT GIPR 6.53E-02 -0.19 -1.27
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05669599) A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
2 An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023 Mar;161:170939.